Trevi Therapeutics, Inc.
TRVI · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | -$0 |
| % Margin | – | – | – | – |
| R&D Expenses | $10 | $9 | $8 | $9 |
| G&A Expenses | $4 | $4 | $4 | $0 |
| SG&A Expenses | $4 | $4 | $4 | $3 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $14 | $14 | $11 | $12 |
| Operating Income | -$14 | -$14 | -$11 | -$12 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $2 | $1 | $1 | $1 |
| Pre-Tax Income | -$12 | -$12 | -$10 | -$11 |
| Tax Expense | -$0 | -$0 | -$0 | $0 |
| Net Income | -$12 | -$12 | -$10 | -$11 |
| % Margin | – | – | – | – |
| EPS | -0.08 | -0.094 | -0.088 | -0.11 |
| % Growth | 15.3% | -7.4% | 20.1% | – |
| EPS Diluted | -0.08 | -0.094 | -0.088 | -0.11 |
| Weighted Avg Shares Out | 145 | 130 | 118 | 106 |
| Weighted Avg Shares Out Dil | 145 | 130 | 118 | 106 |
| Supplemental Information | – | – | – | – |
| Interest Income | $2 | $1 | $1 | $1 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$12 | -$12 | -$10 | -$11 |
| % Margin | – | – | – | – |